SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May. 8, 2013-- Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at two investor conferences this month.

• Bank of America Merrill Lynch 2013 Healthcare Conference: Exelixis’ presentation is scheduled for 11:00 a.m. EDT / 8:00 a.m. PDT on Tuesday, May 14, 2013, in Las Vegas.
• UBS 2013 Global Healthcare Conference: Exelixis’ presentation is scheduled for 9:30 a.m. EDT / 6:30 a.m. PDT on Tuesday, May 21, 2013, in New York.

During each presentation, Dr. Morrissey will review the company’s development plans and priorities for cabozantinib in 2013. He will also discuss the company’s corporate strategy and financial outlook, and provide a general business update.

Each presentation will be webcast and may be access via the Event Calendar page under Investors & Media at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ™ (cabozantinib). Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.

Source: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
cbutler@exelixis.com